title: The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species.
abstract: Exophiala jeanselmei is clinically redefined as a rare agent of subcutaneous lesions of traumatic origin, eventually causing eumycetoma. Mycetoma is a localized, chronic, suppurative subcutaneous infection of tissue and contiguous bone after a traumatic inoculation of the causative organism. In advanced stages of the infection, one finds tumefaction, abscess formation and draining sinuses. The species has been described as being common in the environment, but molecular methods have only confirmed its occurrence in clinical samples. Current diagnostics of E. jeanselmei is based on sequence data of the Internal Transcribed Spacer (ITS) region of ribosomal DNA (rDNA), which sufficiently reflects the taxonomy of this group. The first purpose of this study was the re-identification of all clinical (n=11) and environmental strains (n=6) maintained under the name E. jeanselmei, and to establish clinical preference of the species in its restricted sense. Given the high incidence of eumycetoma in endemic areas, the second goal of this investigation was the evaluation of in vitro susceptibility of E.jeanselmei to eight conventional and new generations of antifungal drugs to improve antifungal therapy in patients. As an example, we describe a case of black grain mycetoma in a 43-year-old Thai male with several draining sinuses involving the left foot. The disease required extensive surgical excision coupled with intense antifungal chemotherapy to achieve cure. In vitro studies demonstrated that posaconazole and itraconazole had the highest antifungal activity against E. jeanselmei and E. oligosperma for which high MICs were found for caspofungin. However, their clinical effectiveness in the treatment of Exophiala infections remains to be determined.
authors.affiliation: CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands.
authors.forename: H
authors.initials: H
authors.lastname: Badali
authors.forename: M J
authors.initials: MJ
authors.lastname: Najafzadeh
authors.forename: M
authors.initials: M
authors.lastname: van Esbroeck
authors.forename: E
authors.initials: E
authors.lastname: van den Enden
authors.forename: B
authors.initials: B
authors.lastname: Tarazooie
authors.forename: J F G M
authors.initials: JF
authors.lastname: Meis
authors.forename: G S
authors.initials: GS
authors.lastname: de Hoog
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004271:DNA, Fungal / Q000032:analysis; D021901:DNA, Intergenic / Q000235:genetics; D004275:DNA, Ribosomal / Q000235:genetics; D005093:Exophiala / Q000166:cytology / Q000187:drug effects* / Q000235:genetics; D005533:Foot Dermatoses / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008271:Mycetoma / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D013172:Spores, Fungal / Q000166:cytology
chemical_list: D000935:Antifungal Agents; D004271:DNA, Fungal; D021901:DNA, Intergenic; D004275:DNA, Ribosomal